Journal of Clinical Oncology, Vol 14, 925-934, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen

I Magrath, M Adde, A Shad, D Venzon, N Seibel, J Gootenberg, J Neely, C Arndt, M Nieder, E Jaffe, RA Wittes and ID Horak
Pediatric Branch, National Cancer Institute, Bethesda, MD, USA.

PURPOSE: We have used identical treatment protocols for adults and children with small non-cleaved-cell lymphoma (SNCL) for many years and report here the results of two successive treatment regimens in these age groups. PATIENTS AND METHODS: Seventy-two patients (39 adults and 33 children) were treated with protocol 77-04 between 1977 and 1985. All patients, except those with resected abdominal disease, received 15 cycles of a combination of cyclophosphamide (CTX), doxorubicin (ADR), prednisone (PRED), vincristine (VCR), high-dose methotrexate (MTX), and intrathecal (IT) therapy. Forty-one patients (20 adults and 21 children) were treated with protocol 89-C-41, which has been used since 1989. High-risk patients received four alternating cycles (with a total duration of 12 to 15 weeks) of an intensified version of protocol 77-04 without PRED (CODOX-M), and a new drug combination consisting of ifosfamide, etoposide, high-dose cytarabine (ara-C), and IT MTX (IVAC). Low-risk patients received three cycles of the CODOX-M regimen. High- risk patients were randomized to either receive or not receive granulocyte-macrophage colony-stimulating factor (GM-CSF). RESULTS: Event-free survival (EFS) in protocol 77-04 was 56% at 2 years and beyond. EFS in protocol 89-C-41 was 92% at 2 years and beyond. GM-CSF was associated with increased thrombocytopenia. CONCLUSION: Adults and children with SNCL have a similar prognosis when treated with the same chemotherapy. EFS in high-risk patients has been markedly improved by including IVAC in protocol 89-C-41, and excellent results can be achieved with only four cycles of therapy. In protocol 89-C-41, GM-CSF was not beneficial.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Tholouli, S. Watt, G. S. Lucas, J. Burthem, J. A. L. Yin, J. Cavet, H. Greenfield, and J. B. Houghton Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome Blood, July 9, 2009; 114(2): 485 - 486. [Full Text] [PDF]

				P. J Hosein, D. Morgensztern, F. Coleman, G. Walker, M. Escalon, J. Rosenblatt, and I. S Lossos High Remission Rates and Prolonged Progression Free Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma Treated with R-MACLOIVAM-T Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 3597 - 3597. [Abstract]

				J. Katzel, S. Kempin, D. Vesole, P. Lagmay-Fuentes, W. Cook, and F. Siegal Therapy Related Leukemia in HIV Patients after Treatment for Non-Hodgkin Lymphoma Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 5284 - 5284. [Abstract]

				G. M. Mead, S. L. Barrans, W. Qian, J. Walewski, J. A. Radford, M. Wolf, S. M. Clawson, S. P. Stenning, C. L. Yule, A. S. Jack, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial) Blood, September 15, 2008; 112(6): 2248 - 2260. [Abstract] [Full Text] [PDF]

				V. Raina, K. Medhi, S. Kataria, R. Kumar, A. Chopra, D. Kalita, and P. A. Kadam Burkitt's Leukemia After Treatment of Primary Mediastinal Nonseminomatous Germ Cell Tumor J. Clin. Oncol., May 1, 2008; 26(13): 2212 - 2214. [Full Text] [PDF]

				A J Wills, S O'Connor, and A McMillan Sub-acute demyelinating neuropathy associated with an NK/T cell lymphoma J. Neurol. Neurosurg. Psychiatry, April 1, 2008; 79(4): 484 - 485. [Full Text] [PDF]

				K. H. Albritton, C. H. Wiggins, H. E. Nelson, and J. C. Weeks Site of Oncologic Specialty Care for Older Adolescents in Utah J. Clin. Oncol., October 10, 2007; 25(29): 4616 - 4621. [Abstract] [Full Text] [PDF]

				L. Sung, P. C. Nathan, S. M.H. Alibhai, G. A. Tomlinson, and J. Beyene Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection Ann Intern Med, September 18, 2007; 147(6): 400 - 411. [Abstract] [Full Text] [PDF]

				C. Patte, A. Auperin, M. Gerrard, J. Michon, R. Pinkerton, R. Sposto, C. Weston, M. Raphael, S. L. Perkins, K. McCarthy, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients Blood, April 1, 2007; 109(7): 2773 - 2780. [Abstract] [Full Text] [PDF]

				D. Maruyama, T. Watanabe, Y. Beppu, Y. Kobayashi, S.-W. Kim, K. Tanimoto, A. Makimoto, Y. Kagami, T. Terauchi, Y. Matsuno, et al. Primary Bone Lymphoma: A New and Detailed Characterization of 28 Patients in a Single-Institution Study Jpn. J. Clin. Oncol., March 1, 2007; 37(3): 216 - 223. [Abstract] [Full Text] [PDF]

				J. T. Sandlund Should Adolescents with NHL Be Treated as Old Children or Young Adults? Hematology, January 1, 2007; 2007(1): 297 - 303. [Abstract] [Full Text] [PDF]

				P. Venugopal and S. A. Gregory Lymphoproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 265 - 297. [Full Text] [PDF]

				M. S. Lam Treatment of Burkitt's Lymphoma During Pregnancy Ann. Pharmacother., November 1, 2006; 40(11): 2048 - 2052. [Abstract] [Full Text] [PDF]

				S. S. Dave, K. Fu, G. W. Wright, L. T. Lam, P. Kluin, E.-J. Boerma, T. C. Greiner, D. D. Weisenburger, A. Rosenwald, G. Ott, et al. Molecular diagnosis of Burkitt's lymphoma. N. Engl. J. Med., June 8, 2006; 354(23): 2431 - 2442. [Abstract] [Full Text] [PDF]

				J. A. Ferry Burkitt's Lymphoma: Clinicopathologic Features and Differential Diagnosis. Oncologist, April 1, 2006; 11(4): 375 - 383. [Abstract] [Full Text] [PDF]

				M. Divine, P. Casassus, S. Koscielny, J. Bosq, C. Sebban, C. Le Maignan, A. Stamattoulas, B. Dupriez, M. Raphael, J.-L. Pico, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol Ann. Onc., December 1, 2005; 16(12): 1928 - 1935. [Abstract] [Full Text] [PDF]

				S. T. Lim, R. Karim, B. N. Nathwani, A. Tulpule, B. Espina, and A. M. Levine AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre-Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard Chemotherapy J. Clin. Oncol., July 1, 2005; 23(19): 4430 - 4438. [Abstract] [Full Text] [PDF]

				W. Woessmann, K. Seidemann, G. Mann, M. Zimmermann, B. Burkhardt, I. Oschlies, W.-D. Ludwig, T. Klingebiel, N. Graf, B. Gruhn, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95 Blood, February 1, 2005; 105(3): 948 - 958. [Abstract] [Full Text] [PDF]

				K. A. Blum, G. Lozanski, and J. C. Byrd Adult Burkitt leukemia and lymphoma Blood, November 15, 2004; 104(10): 3009 - 3020. [Abstract] [Full Text] [PDF]

				S. Smeland, A. K. Blystad, S. O. Kvaloy, I. M. Ikonomou, J. Delabie, G. Kvalheim, J. Hammerstrom, G. F. Lauritzsen, and H. Holte Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens Ann. Onc., July 1, 2004; 15(7): 1072 - 1078. [Abstract] [Full Text] [PDF]

				G. M. Mead, M. R. Sydes, J. Walewski, A. Grigg, C. S. Hatton, P. Norbert, C. Guarnaccia, M. S. Lewis, J. McKendrick, S. P. Stenning, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study Ann. Onc., August 1, 2002; 13(8): 1264 - 1274. [Abstract] [Full Text] [PDF]

				C. Patte, A. Laplanche, A. I. Bertozzi, A. Baruchel, D. Frappaz, C. Schmitt, F. Mechinaud, B. Nelken, P. Boutard, and J. Michon Granulocyte Colony-Stimulating Factor in Induction Treatment of Children With Non-Hodgkin's Lymphoma: A Randomized Study of the French Society of Pediatric Oncology J. Clin. Oncol., January 15, 2002; 20(2): 441 - 448. [Abstract] [Full Text] [PDF]

				E. J. Lee, G. R. Petroni, C. A. Schiffer, C. E. Freter, J. L. Johnson, M. Barcos, G. Frizzera, C. D. Bloomfield, and B. A. Peterson Brief-Duration High-Intensity Chemotherapy for Patients With Small Noncleaved-Cell Lymphoma or FAB L3 Acute Lymphocytic Leukemia: Results of Cancer and Leukemia Group B Study 9251 J. Clin. Oncol., October 15, 2001; 19(20): 4014 - 4022. [Abstract] [Full Text] [PDF]

				C. Patte, A. Auperin, J. Michon, H. Behrendt, G. Leverger, D. Frappaz, P. Lutz, C. Coze, Y. Perel, M. Raphael, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia Blood, June 1, 2001; 97(11): 3370 - 3379. [Abstract] [Full Text] [PDF]

				S. Imashuku, K. Kuriyama, T. Teramura, E. Ishii, N. Kinugawa, M. Kato, M. Sako, and S. Hibi Requirement for Etoposide in the Treatment of Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis J. Clin. Oncol., May 15, 2001; 19(10): 2665 - 2673. [Abstract] [Full Text] [PDF]

				J. L. Hecht and J. C. Aster Molecular Biology of Burkitt's Lymphoma J. Clin. Oncol., November 1, 2000; 18(21): 3707 - 3721. [Abstract] [Full Text] [PDF]

				S. Gururangan, R. Sposto, M. S. Cairo, A. T. Meadows, and J. L. Finlay Outcome Of CNS Disease At Diagnosis in Disseminated Small Noncleaved-Cell Lymphoma and B-Cell Leukemia: A Children's Cancer Group Study J. Clin. Oncol., May 10, 2000; 18(10): 2017 - 2025. [Abstract] [Full Text] [PDF]

				T. Akasaka, H. Akasaka, C. Ueda, N. Yonetani, Y. Maesako, A. Shimizu, H. Yamabe, S. Fukuhara, T. Uchiyama, and H. Ohno Molecular and Clinical Features of Non-Burkitt’s, Diffuse Large-Cell Lymphoma of B-Cell Type Associated With the c-MYC/Immunoglobulin Heavy-Chain Fusion Gene J. Clin. Oncol., February 1, 2000; 18(3): 510 - 510. [Abstract] [Full Text] [PDF]

				A. Reiter, M. Schrappe, M. Tiemann, W.-D. Ludwig, E. Yakisan, M. Zimmermann, G. Mann, A. Chott, W. Ebell, T. Klingebiel, et al. Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90 Blood, November 15, 1999; 94(10): 3294 - 3306. [Abstract] [Full Text] [PDF]

				J. Cortes, L. Fayad, S. O'Brien, M. Keating, and H. Kantarjian Persistence of Peripheral Blood and Bone Marrow Blasts during Remission Induction in Adult Acute Lymphoblastic Leukemia Confers a Poor Prognosis Depending on Treatment Intensity Clin. Cancer Res., September 1, 1999; 5(9): 2491 - 2497. [Abstract] [Full Text] [PDF]

				Ch. Jung, M. Gross, U. Kronawitter, S. Danhauser-Riedl, F.-D. Goebel, and D. Schlondorff Two Uncommon Lymphomas J. Clin. Oncol., February 1, 1999; 17(2): 726 - 726. [Full Text] [PDF]

				A. Wirth, H. M. Prince, M. Wolf, U. Machida, M. Kami, H. Hirai, N. Mounier, C. Gisselbrecht, E. Lepage, C. Kosmas, et al. Treatment of Intermediate-Grade and High-Grade Non-Hodgkin's Lymphoma N. Engl. J. Med., November 12, 1998; 339(20): 1475 - 1477. [Full Text]

				A. Nademanee, A. Molina, M. R. O'Donnell, A. Dagis, D. S. Snyder, P. Parker, A. Stein, E. Smith, I. Planas, A. Kashyap, et al. Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group Blood, November 15, 1997; 90(10): 3844 - 3852. [Abstract] [Full Text] [PDF]

				M. Smith, J. Abrams, E. L. Trimble, and R. S. Ungerleider Dose Intensity of Chemotherapy for Childhood Cancers Oncologist, October 1, 1996; 1(5): 293 - 304. [Abstract] [Full Text] [PDF]

				J. T. Sandlund, J. R. Downing, and W. M. Crist Non-Hodgkin's Lymphoma in Childhood N. Engl. J. Med., May 9, 1996; 334(19): 1238 - 1248. [Full Text] [PDF]